Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to tr…
Drug Manufacturers - General
US, Thousand Oaks [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | -13.79 | 1.42 | 1.65 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | 32.09 | 23.22 | 17.58 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | -19.57 | 9.37 | 11.65 | |
| Cash | -55.73 | 18.11 | 40.91 | |
| Capex | 7.80 | -0.43 | -0.47 | |
| Free Cash Flow | 58.53 | 0.86 | 0.54 | |
| Revenue | -9.93 | 13.80 | 15.32 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | -8.54 | 0.57 | 0.62 | |
| Operating Margin | -18.04 | 0.13 | 0.16 | |
| ROA | -84.61 | < 0.005 | < 0.005 | |
| ROE | -81.72 | -0.02 | 0.12 | |
| ROIC | 40.09 | 0.02 | 0.02 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of AMGN is permitted for members.
5
Growth
The "Growth Entry" for the Focus of AMGN is permitted for members.
6
Leverage & Liquidity